9 years ago

Kymab Raises US$100 Million in Series C Funding

  • Kymab, a UK-based monoclonal antibody biopharmaceutical company, secured US$100 million in Series C funding led by ORI Healthcare Fund with participation from Shenzhen Hepalink Pharmaceutical, Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation plc, CF Woodford Equity Income Fund and Woodford Patient Capital plc

  • The funds will be used to advance Kymab's proprietary pipeline of therapeutic human monoclonal antibodies.

      • ProblemHealthcare

      "Finding effective treatments for diseases like cancer, autoimmune disorders, and infections is challenging. Current treatments often have severe side effects and are not always successful."

      Solution

      "Kymab develops fully human monoclonal antibodies that target specific proteins involved in immune responses, offering a safer and more effective way to treat diseases. Their proprietary Kymouse platform allows them to create a wide range of antibody drugs for various applications."

      Covered on